Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes

The 2019 European Society of Cardiology guidelines for the management of dyslipidemia consider the use of high-dose marine omega-3 fatty acid (FA) eicosapentaenoic acid (EPA) supplementation (icosapent ethyl 2 × 2g/day) to lower residual cardiovascular risk in high-risk patients with hypertriglyceri...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Atherosclerosis plus Ročník 58; s. 1 - 8
Hlavní autoři: Follonier, Cédric, Rabassa, Gabriel, Branca, Mattia, Carballo, David, Koskinas, Konstantinos, Heg, Dik, Nanchen, David, Räber, Lorenz, Klingenberg, Roland, Haller, Moa Lina, Carballo, Sebastian, Windecker, Stephan, Matter, Christian M., Rodondi, Nicolas, Mach, François, Gencer, Baris
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 01.12.2024
Elsevier
Témata:
Acute coronary syndrome
Dyslipidemia
Full Length
Heart disease risk factor
Hypertriglyceridemia
Omega-3 fatty acids
Secondary prevention
Secondary prevention
Acute coronary syndrome
Hypertriglyceridemia
Omega-3 fatty acids
Dyslipidemia
Heart disease risk factor
ISSN:2667-0895, 2667-0909, 2667-0895
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The 2019 European Society of Cardiology guidelines for the management of dyslipidemia consider the use of high-dose marine omega-3 fatty acid (FA) eicosapentaenoic acid (EPA) supplementation (icosapent ethyl 2 × 2g/day) to lower residual cardiovascular risk in high-risk patients with hypertriglyceridemia. This study aimed to assess the eligibility for omega-3 FA-EPA supplementation in patients with acute coronary syndromes (ACS). In a prospective Swiss cohort of patients hospitalized for ACS, eligibility for marine omega-3 FA-EPA, defined as plasma triglyceride levels ranging from 1.5 to 5.6 mmol/l, was assessed at baseline and one-year follow-up and compared across subgroups. Lipid-lowering therapy intensification with statin and ezetimibe was modelled to simulate a hypothetical systematic treatment and its effect on omega-3 FA-EPA supplementation eligibility. Of 2643 patients, 98 % were prescribed statin therapy at discharge, including 62 % at a high-intensity regimen; 93 % maintained it after one year, including 53 % at a high-intensity regimen. The use of ezetimibe was 3 % at discharge and 7 % at one year. Eligibility was observed in 32 % (32 % men, 29 % women) one year post-ACS. After modelling systematic treatment with statins, ezetimibe, and both, eligibility decreased to 31 %, 25 % and 24 %, respectively. Eligibility was higher in individuals aged <70 (34 vs 25 %), smokers (38 vs 28 %), diabetics (46 vs 29 %), hypertensive (35 vs 29 %), and obese patients (46 vs 22 % for normal weight), all with p-values <0.001. In a contemporary Swiss cohort of patients with ACS, up to 32 % would be eligible for omega-3 FA-EPA supplementation one year after ACS, highlighting an opportunity to mitigate residual cardiovascular risk in patients with ACS and hypertriglyceridemia. •High-dose omega-3 fatty acid eicosapentaenoic acid (FA-EPA) supplementation has been shown to lower cardiovascular risk in high-risk patients with hypertriglyceridemia.•Up to 1 in 3 patients were eligible for omega-3 FA-EPA supplementation one year after acute coronary syndromes.•Eligibility for omega-3 FA-EPA is higher in those <70 years old and in smokers, diabetics, hypertensive, and obese patients.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally.
ISSN:2667-0895
2667-0909
2667-0895
DOI:10.1016/j.athplu.2024.09.002